Paxlovid, Pfizer’s COVID-19 oral antiviral shows the risk of hospitalisation or death is reduced by nearly 90%

FANTASTIC news for your Friday! Phase 2/3 results of PAXLOVID, Pfizer’s COVID-19 oral antiviral shows the risk of hospitalization or death is REDUCED by NEARLY 90% in high-risk adults with COVID-19 when taken within three days of experiencing symptoms.

Let’s talk about that! 🧵

— Chise 🧬🧫🦠💉 BWS GoH (@sailorrooscout) November 5, 2021